Physician Data Query

Last uploaded: August 27, 2019
Preferred Name

brentuximab vedotin

Synonyms

Adcetris

Definitions

An antibody-drug conjugate (ADC) directed against the tumor necrosis factor (TNF) receptor CD30 with potential antineoplastic activity. Brentuximab vedotin is generated by conjugating the humanized anti-CD30 monoclonal antibody SGN-30 to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline peptide linker. Upon administration and internalization by CD30-positive tumor cells, brentuximab vedotin undergoes enzymatic cleavage, releasing MMAE into the cytosol; MMAE binds to tubulin and inhibits tubulin polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. Transiently activated during lymphocyte activation, CD30 (tumor necrosis factor receptor superfamily, member 8;TNFRSF8) may be constitutively expressed in hematologic malignancies including Hodgkin lymphoma and some T-cell non-Hodgkin lymphomas. The linkage system in brentuximab vedotin is highly stable in plasma, resulting in cytotoxic specificity for CD30-positive cells. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C66944" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C66944" NCI Thesaurus)

ID

http://purl.bioontology.org/ontology/PDQ/CDR0000530758

altLabel

Adcetris

antibody-drug conjugate SGN-35

anti-CD30 ADC SGN-35

anti-CD30 antibody-drug conjugate SGN-35

SGN-35

cAC10-vcMMAE

CAS Registry

914088-09-8

cui

C2973446

C3192355

C1832035

DATE FIRST PUBLISHED

2007-01-16

Date last modified

2016-05-10

definition

An antibody-drug conjugate (ADC) directed against the tumor necrosis factor (TNF) receptor CD30 with potential antineoplastic activity. Brentuximab vedotin is generated by conjugating the humanized anti-CD30 monoclonal antibody SGN-30 to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline peptide linker. Upon administration and internalization by CD30-positive tumor cells, brentuximab vedotin undergoes enzymatic cleavage, releasing MMAE into the cytosol; MMAE binds to tubulin and inhibits tubulin polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. Transiently activated during lymphocyte activation, CD30 (tumor necrosis factor receptor superfamily, member 8;TNFRSF8) may be constitutively expressed in hematologic malignancies including Hodgkin lymphoma and some T-cell non-Hodgkin lymphomas. The linkage system in brentuximab vedotin is highly stable in plasma, resulting in cytotoxic specificity for CD30-positive cells. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C66944" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C66944" NCI Thesaurus)

LT

TRD

NCI ID

C66944

notation

CDR0000530758

ORIG STY

Drug/agent

prefLabel

brentuximab vedotin

tui

T116

T129

T121

Delete Subject Author Type Created
No notes to display
Create New Mapping

Delete Mapping To Ontology Source
http://purl.bioontology.org/ontology/SCTSPA/714671006 SCTSPA CUI
http://purl.bioontology.org/ontology/MESH/C547738 MESH CUI
http://purl.bioontology.org/ontology/MESH/C547738 MESH CUI
http://purl.bioontology.org/ontology/MESH/C547738 MESH CUI
http://purl.bioontology.org/ontology/MESH/C547738 MESH LOOM
http://purl.bioontology.org/ontology/SCTSPA/713395006 SCTSPA CUI
http://purl.obolibrary.org/obo/dinto_DB08870 DINTO LOOM
http://purl.bioontology.org/ontology/RXNORM/1147320 RXNORM CUI
http://purl.bioontology.org/ontology/RXNORM/1147320 RXNORM LOOM
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C66944 NCIT LOOM
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C66944 NCIT LOOM
http://purl.bioontology.org/ontology/NDFRT/N0000183555 NDFRT CUI
http://purl.bioontology.org/ontology/NDFRT/N0000183555 NDFRT LOOM
http://purl.obolibrary.org/obo/DRON_00020132 DRON LOOM
http://purl.obolibrary.org/obo/DRON_00020132 DRON LOOM
http://purl.bioontology.org/ontology/SNOMEDCT/713395006 SNOMEDCT CUI
http://purl.bioontology.org/ontology/SNOMEDCT/713395006 SNOMEDCT LOOM
http://purl.bioontology.org/ontology/UATC/L01XC12 ATC CUI
http://purl.bioontology.org/ontology/UATC/L01XC12 ATC LOOM
http://purl.bioontology.org/ontology/VANDF/4031047 VANDF CUI
http://purl.bioontology.org/ontology/VANDF/4031047 VANDF LOOM
http://purl.bioontology.org/ontology/SNOMEDCT/714671006 SNOMEDCT CUI
http://purl.bioontology.org/ontology/NDDF/013904 NDDF CUI
http://purl.bioontology.org/ontology/NDDF/013904 NDDF LOOM
http://purl.bioontology.org/ontology/RXNORM/1147324 RXNORM CUI
http://purl.jp/bio/4/id/201206090882884997 IOBC LOOM